2012 DNA Targeted Protein Degradation Therapies 
Drug Discovery World
OCTOBER 16, 2023
A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases. CellProthera also appointed the Newcastle Centre for Life’s GMP cell therapy centre to produce the ATMP.”
Drug Target Review
OCTOBER 4, 2023
2 In response, DNA-damaging agents that could target the entire cell cycle received renewed attention as ADC payloads. 9 Others, like psymberin, have been used as ADC payloads, with a β-glucuronide linker to target CD-30-positive and CD-70-positive malignancies. Fu Y, Ho M. 1 , 33–43 (2018). Cancers 11 , 394 (2019).
Expert insights. Personalized for you.
190 
Let's personalize your content